Thus, to replace protein-based radiotracers for the visualization of EGFR-positive tumor lesions by a radiopeptide, the next step is to develop or identify a suitable peptidic receptor ligand that exhibits a sufficiently strong EGFR interaction profile. This evidence concerns the gene EGFR and neoplasm.